Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

Recruiting now · Not applicable

Conditions studied: Renal Cell Carcinoma

In brief

This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).

Key facts

Study ID

NCT05023265

Run by

Sunnybrook Health Sciences Centre

People needed

70

Starts

2022-02-08

Expected to finish

2026-10-01

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients ≥18 years old
• Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
• Primary lesion >3 cm, or recurrent lesion following local ablative therapy
• Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting
• ECOG 0-2
• Written informed consent
• Participants must be able to understand the English-language or with the aid of a translator

You may not qualify if…

• Primary Lesion >20cm
• Evidence of distant metastatic disease
• Previous abdominal RT in vicinity of kidney preventing definitive SBRT
• History of major radiosensitivity syndrome
• Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)
• Currently pregnant or lactating

Where it is running

• Sunnybrook Health Sciences — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.